Latest / The Dales Report | Trade to Black
Cannabis Medical Markets Are Growing, So What's Next? | TTB Presented by Flowhub
James Yamanaka, CEO of Organigram Global (NASDAQ: OGI), logs on to break down record Q3 fiscal 2026 results, net revenue of $105.8 million, up 49% year-over-year, and net income of $76.2 million, or $0.56 per share. Adjusted EBITDA surged 136% to $13.4 million, with the newly consolidated Sanity Group in Germany contributing roughly €25 million in net revenue. Organigram continues to hold the top overall market share position in Canada, leading in vapes and milled flower, with strong positions across concentrates, flower, and pre-rolls. Shadd and James also get into European expansion…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.